Diagnostic accuracy of the Fibrosis-4 (FIB-4) index for advanced liver fibrosis in Qatari patients with MASLD: Comparison with liver biopsy and FibroScan
Moataz Derbala, Ibrahim M. Obeidat, Raya Abualsuod, Mahmoud Draidi, Nagah Selim, Jihene Maatoug, Alaa Elkalamawi · 2026
Read Diagnostic accuracy of the Fibrosis-4 (FIB-4) index for advanced liver fibrosis in Qatari patients with MASLD: Comparison with liver biopsy and FibroScan by Moataz Derbala, Ibrahim M. Obeidat, Raya Abualsuod, Mahmoud Draidi, Nagah Selim, Jihene Maatoug, Alaa Elkalamawi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13430814.txt.
Description
Moataz Derbala and colleagues test the FIB-4 score for spotting advanced liver scarring in Qatari residents with metabolic fatty liver disease. Scarring stage drives long-term outlook, and FIB-4 is urged as a first non-invasive screen, yet its accuracy may shift across populations.
Adults with the disease seen at Hamad Medical Corporation in Qatar from 2023 to 2024 were reviewed, with FIB-4 computed from routine blood tests. Liver biopsy served as the main truth standard, with FibroScan as a second comparison. Clinics in Qatar get a local verdict on whether a cheap blood-based score can be trusted to flag advanced scarring.
Catalog record
| CREATOR | Moataz Derbala, Ibrahim M. Obeidat, Raya Abualsuod, Mahmoud Draidi, Nagah Selim, Jihene Maatoug, Alaa Elkalamawi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |